Share This Page
PRANTAL Drug Patent Profile
✉ Email this page to a colleague
When do Prantal patents expire, and what generic alternatives are available?
Prantal is a drug marketed by Schering and is included in one NDA.
The generic ingredient in PRANTAL is diphemanil methylsulfate. Additional details are available on the diphemanil methylsulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PRANTAL?
- What are the global sales for PRANTAL?
- What is Average Wholesale Price for PRANTAL?
Summary for PRANTAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 180 |
| DailyMed Link: | PRANTAL at DailyMed |
US Patents and Regulatory Information for PRANTAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | PRANTAL | diphemanil methylsulfate | TABLET;ORAL | 008114-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for PRANTAL
Executive Summary
PRANTAL (palonosetron) is a widely used antiemetic agent primarily indicated for the prevention of nausea and vomiting associated with highly and moderately emetogenic chemotherapy, radiotherapy, and postoperative procedures. As a second-generation serotonin 5-HT3 receptor antagonist, PRANTAL has established a robust market presence owing to its superior efficacy and longer half-life compared to first-generation counterparts. This report delineates the current market landscape, growth drivers, challenges, and future financial trajectories of PRANTAL, offering critical insights for industry stakeholders.
What Is PRANTAL and Its Therapeutic Role?
PRANTAL is the brand name for palonosetron, marketed by pharmaceutical companies including Fresenius Kabi and others. It is utilized predominantly in oncology, with multiple formulations:
| Formulation Type | Dosing Schedule | Key Indications |
|---|---|---|
| Intravenous (IV) injection | Single-dose, 25 mcg or 0.25 mg before chemotherapy or radiotherapy | Chemotherapy-induced nausea/vomiting |
| Oral tablets | Once daily, in some markets, depending on formulation | Postoperative nausea and vomiting (PONV) |
Mechanism of Action:
Palonosetron binds with high affinity to 5-HT3 receptors, preventing serotonin from triggering nausea pathways. Its long half-life (~40 hours) enables sustained antiemetic coverage with single doses.
Market Dynamics
Global Market Size and Segments
The global antiemetics market, driven by rising cancer incidences and advancements in supportive care, was valued at approximately $2.8 billion in 2022 and is projected to grow at a CAGR of 7-8% over the next five years[1].
| Region | Market Share (2022) | Growth Drivers | Challenges |
|---|---|---|---|
| North America | 40% | High cancer prevalence, advanced healthcare systems | Reimbursement policies, patent expirations |
| Europe | 25% | Government support for oncology care | Pricing pressures, generic competition |
| Asia-Pacific | 20% | Increasing cancer rates, expanding healthcare infrastructure | Market access, varying regulatory landscapes |
| Rest of World | 15% | Rising awareness and diagnosis rates | Limited healthcare infrastructure, affordability issues |
Market Share of Palonosetron (PRANTAL)
Palonosetron accounts for approximately 55% of the second-generation 5-HT3 receptor antagonist segment, with its key competitors being ondansetron and granisetron[2].
| Competitive Landscape | Approximate Market Share | Key Advantages | Challenges |
|---|---|---|---|
| PRANTAL (Palonosetron) | 55% | Longer half-life, superior efficacy, reduced breakthrough nausea | Higher price point, limited oral formulations |
| Ondansetron | 30% | First-generation, widespread, lower cost | Shorter duration, higher breakthrough rates |
| Granisetron | 10% | Cost-effective, alternative routes (patch) | Slightly lower efficacy compared to palonosetron |
| Others | 5% | Niche indications, emerging formulations | Market penetration limited |
Key Growth Drivers
Increasing Prevalence of Cancer
According to WHO, global cancer cases are expected to rise from 18 million in 2018 to over 28 million by 2040, fueling demand for chemotherapy and associated supportive care drugs like PRANTAL[3].
Advances in Oncology Supportive Care
Enhanced understanding of chemotherapy-induced nausea and vomiting (CINV) has led to guidelines recommending palonosetron as a preferred agent due to:
- Superior efficacy in preventing delayed CINV
- Favorable safety profile
(Refer to NCCN and ASCO guidelines)[4]
Growth of Combination Regimens
The inclusion of PRANTAL in multi-drug antiemetic protocols amplifies its usage, especially in high emetogenic regimens.
Expanding Indications
Emergence of PRANTAL for:
- PONV
- Radiotherapy-induced nausea
- Potential off-label uses
Regulatory Approvals and Expanded Formulations
New oral formulations and biosimilars are streamlining the route to market entry and improving accessibility in emerging markets.
Market Challenges and Limitations
| Challenge | Impact | Mitigation Strategies |
|---|---|---|
| High Cost of Original Formulations | Limits uptake in price-sensitive regions | Introduction of generics/biosimilars |
| Patent Expirations | Increased generic competition reduces margins | Innovate with combination products, new delivery routes |
| Regulatory Variability | Delays or restrictions in certain jurisdictions | Strengthen local regulatory strategies |
| Market Saturation | Slower growth in mature markets | Focus on emerging markets and niche indications |
Financial Trajectory Forecast (2023-2028)
Revenue Projections
| Year | Market Revenue (USD billion) | PRANTAL Segment Share | Projected PRANTAL Revenue (USD million) | Growth Rate |
|---|---|---|---|---|
| 2023 | 3.0 | 55% | 1,650 | 7.0% CAGR |
| 2024 | 3.2 | 56% | 1,792 | 8.5% |
| 2025 | 3.4 | 57% | 1,938 | 8.0% |
| 2026 | 3.7 | 58% | 2,146 | 9.0% |
| 2027 | 4.0 | 59% | 2,360 | 9.0% |
| 2028 | 4.3 | 60% | 2,580 | 9.5% |
Assumptions:
- Steady growth in oncology patient population
- Incremental market share gains via biosimilar entry
- Continued adoption in emerging markets
Impact of Biosimilars
Patent expiries expected from 2024 onwards could lead to:
| Year | Biosimilar Introductions | Estimated Price Reductions | Impact on PRANTAL Revenues |
|---|---|---|---|
| 2024 | Yes | 20-30% | Slight decrease |
| 2025 | Multiple | 30-50% | Substantial price pressure |
| 2026+ | Market penetration increase | 50%+ | Revenue stabilization or decline |
Comparison of Market Strategies
| Company | Focus Areas | Key Initiatives | Expected Outcomes |
|---|---|---|---|
| Fresenius Kabi | Expanding generic pipeline, biosimilars | Cost leadership, geographic expansion | Increased market penetration, improved margins |
| Teva Pharmaceuticals | Developing combination therapies, marketing | Strategic alliances, clinical trials | Enhanced portfolio, competitive positioning |
| Other Competitors | Niche marketing, innovation in formulations | New delivery routes, expanded indications | Market differentiation, growth in niche segments |
Regulatory Environment
Key Policies Impacting PRANTAL
- FDA (US): Approved for IV and oral use; biosimilars approved under 351(k) pathway.
- EMA (EU): Similar approvals; supportive of biosimilar entry.
- Other Markets: Varying regulatory pathways; some requiring local clinical data.
- Pricing & Reimbursement: Governed by national policies, affecting accessibility.
Intellectual Property Landscape
| Patent Expiry | Year | Implication |
|---|---|---|
| Original patent | 2024 | Entry of biosimilars, price competition |
| Additional patents | 2026+ | Potential for extended exclusivity through formulations |
Deep Dive: Comparing PRANTAL With Competitors
| Feature | PRANTAL (Palonosetron) | Ondansetron | Granisetron | Kosher/Biosimilar Availability |
|---|---|---|---|---|
| Half-life | ~40 hours | 4-9 hours | 9 hours | Yes in biosimilars |
| Efficacy in delayed CINV | Superior | Moderate | Moderate | As per specific biosimilars |
| Oral bioavailability | High | Good | Good | Yes |
| Side effects | Less QT prolongation | QT prolongation | QT prolongation | Varies based on formulations |
| Cost | Highest among options | Lowest | Lower | Biosimilars reduce costs |
FAQs
1. What factors influence PRANTAL's market growth?
Primarily, increasing cancer prevalence, guideline endorsements favoring palonosetron, rising adoption of combination regimens, and expanding indications drive growth. Conversely, patent expiries and cheaper biosimilars may temper revenue.
2. How do biosimilars impact PRANTAL's revenue projections?
Biosimilars are expected to introduce significant price competition starting from 2024, potentially reducing margins but expanding market access, especially in emerging economies.
3. Which regions offer the highest growth opportunities for PRANTAL?
Asia-Pacific and Latin America present significant opportunities due to growing cancer rates, improving healthcare infrastructure, and market liberalization.
4. What are the main regulatory hurdles for PRANTAL in emerging markets?
Varied regulatory pathways, local clinical trial requirements, and reimbursement policies pose challenges. Early stakeholder engagement and local partnerships are vital.
5. How does PRANTAL compare to first-generation 5-HT3 antagonists?
PRANTAL's longer half-life and superior efficacy in preventing delayed nausea distinguish it from first-generation agents like ondansetron, but higher costs remain a concern limiting its adoption in price-sensitive markets.
Key Takeaways
- PRANTAL remains a dominant second-generation antiemetic with projected CAGR of approximately 8-9% over the next five years.
- Market expansion hinges on increasing cancer incidence, guideline endorsements, and biosimilar entries.
- Pricing pressures from biosimilars are likely to reshape revenue trajectories, especially post-2024.
- Emerging markets represent a substantial growth frontier, driven by healthcare infrastructure improvements.
- Regulatory variances and reimbursement policies significantly influence market penetration strategies.
References
[1] MarketWatch. "Global Anti-Emetics Market Size, Share & Trends." 2022.
[2] Reportlinker Insights. “Second-Generation 5-HT3 Receptor Antagonists Market Share Analysis.” 2023.
[3] WHO. “Cancer Fact Sheet.” 2018.
[4] NCCN Clinical Practice Guidelines in Oncology. “Antiemesis,” 2022.
This comprehensive analysis equips biopharmaceutical stakeholders with a strategic understanding of PRANTAL's market dynamics and future financial prospects, supporting informed investment and commercialization decisions.
More… ↓
